ADCendo

Copenhagen, Capital Region, Denmark

Company profile

ADCendo company profile

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.

Business identity

Website: http://adcendo.dk/
Contact email: [email protected]
Operating status: Active
Company type: For Profit
Employee range: 00011-00050 employees
Revenue range: $0+
Founded: 2017-01-01

Headquarters

Headquarters: Copenhagen, Capital Region, Denmark
Country code: DK
Continent: Europe

Capital profile

Funding and company signals

Funding stage: Early Stage Venture
Funding rounds: 6
Total equity funding: $248.1M
Last funding: Series B / $135M / 2024-11-25
Last equity funding: Series B / $135M
Investors: 14
Lead investors: 6
Founders: 4
Articles: 45

Categories and groups

Biotechnology Health Care Biotechnology Health Care Science and Engineering

Founders and investors

Founders

Christoffer NielsenHenrik StageLars H. EngelholmNiels Behrendt

Lead investors

Dawn BiopharmaNovo HoldingsNovo Nordisk FoundationPontifaxTCG CrossoverYsios Capital

Investors

Novo HoldingsOrbiMedRA Capital ManagementTCG CrossoverTPG

People at this company

Preview only. Contact details are available after you sign in.

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Shipment records and coverage can change as the dataset is updated.